GoPath is pleased to announce a strategic agreement with MEDx (Suzhou) Translation Medicine, CO. Ltd to promote a mutual business partnership in developing biopharma services in China and United States.
This comprehensive strategic collaborative partnership is established with the intention to bring both parties’ respective advantages to provide high quality services to our BioPharma clients. GoPath would support MEDx customers from the US and other countries who request clinical trials and researches in the US based on GoPath’s CLIA and CAP dual-certified labs in Chicago, IL. And MEDx is expected to provide GoPath’s clients in China with testing services in compliance with CAP accreditation and with help of product R&D requested by GoPath’s customers.
The partnership is non-exclusive, but both parties are intended to keep a long term relationship to work together in serving our BioPharma clients.
This comprehensive strategic collaborative partnership is established with the intention to bring both parties’ respective advantages to provide high quality services to our BioPharma clients. GoPath would support MEDx customers from the US and other countries who request clinical trials and researches in the US based on GoPath’s CLIA and CAP dual-certified labs in Chicago, IL. And MEDx is expected to provide GoPath’s clients in China with testing services in compliance with CAP accreditation and with help of product R&D requested by GoPath’s customers.
The partnership is non-exclusive, but both parties are intended to keep a long term relationship to work together in serving our BioPharma clients.